Literature DB >> 10974321

GTP differentially affects antagonist radioligand binding to adenosine A(1) and A(2A) receptors in human brain.

B Kull1, P Svenningsson, H Hall, B B Fredholm.   

Abstract

The effect of guanosine triphosphate (GTP) on the interaction of antagonists with human adenosine A(1) and A(2A) receptors was studied using whole-hemisphere sections from human brain and membranes from Chinese hamster ovary (CHO) cells expressing human A(1) and A(2A) receptors. Adenosine A(1) receptors, studied using [3H]1,3-dipropyl-8-cyclopentylxanthine ([3H]DPCPX) as radioligand, showed the expected regional distribution in human brain. Addition of 500 microM GTP significantly increased (23-55%) [3H]DPCPX binding in all regions measured. In CHO cells transfected with human adenosine A(1) receptor cDNA, the number of receptors, B(max), increased from 401 (359-442) to 667 (592-743) fmol/mg protein upon addition of GTP. [3H]5-Amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo-[4,3-e]-1,2, 4-triazolo-[1,5-c]-pyrimidine ([3H]SCH 58261), a selective adenosine A(2A) receptor ligand, showed saturable binding to membranes from CHO cells transfected with adenosine A(2A) receptor cDNA and was localized to striatum and globus pallidus in human brain sections. Addition of GTP did not significantly change [3H]SCH 58261 binding to brain sections or CHO cell membranes. These results indicate that human A(1) and A(2A) receptors are not substantially different from those of the rat as regards regulation by GTP and interactions with endogenous adenosine in binding experiments. However, the relative abundance of the receptors differs between species, and this may be related to the differences observed in the potency of the endogenous agonist.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974321     DOI: 10.1016/s0028-3908(00)00081-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  5 in total

1.  Design, synthesis and evaluation of amino-3,5-dicyanopyridines and thieno[2,3-b]pyridines as ligands of adenosine A1 receptors for the potential treatment of epilepsy.

Authors:  Gaofenngwe Nkomba; Gisella Terre'Blanche; Helena D Janse van Rensburg; Lesetja J Legoabe
Journal:  Med Chem Res       Date:  2022-05-24       Impact factor: 2.351

2.  Species comparison of adenosine receptor subtypes in brain and testis.

Authors:  Gino Giannaccini; Laura Betti; Lionella Palego; Laura Fabbrini; Lara Schmid; Maura Castagna; Laura Giusti; Giovanni Mascia; Antonio Lucacchini
Journal:  Neurochem Res       Date:  2007-11-07       Impact factor: 3.996

Review 3.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

4.  Characterization of human and rodent native and recombinant adenosine A(2B) receptors by radioligand binding studies.

Authors:  Daniela C G Bertarelli; Martina Diekmann; Alaa M Hayallah; Dorothee Rüsing; Jamshed Iqbal; Birgit Preiss; Eugen J Verspohl; Christa E Müller
Journal:  Purinergic Signal       Date:  2006-07-08       Impact factor: 3.765

Review 5.  Allosteric Interactions between Adenosine A2A and Dopamine D2 Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging.

Authors:  Kavya Prasad; Erik F J de Vries; Philip H Elsinga; Rudi A J O Dierckx; Aren van Waarde
Journal:  Int J Mol Sci       Date:  2021-02-09       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.